One year af­ter leav­ing GSK, Em­manuel Hanon jumps to Medicxi-backed vac­cine start­up with an eye on RSV

Af­ter 20 years of ser­vice at GSK — lead­ing glob­al vac­cines R&D for the last sev­en — Em­manuel Hanon left last year for a well­ness com­pa­ny with a gut mi­cro­bio­me fo­cus called Viome.

One of the ma­jor rea­sons for the de­par­ture, ac­cord­ing to him, was in essence to learn some­thing new and to be ex­posed to a new en­vi­ron­ment.

But it didn’t take long for him to re­turn to the vac­cine world full-time. Hanon has now tak­en the top po­si­tion at a Medicxi-backed biotech work­ing on a vac­cine for RSV called Vice­bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER